![](http://cdn.i.haymarketmedia.asia/?n=finance-asia%2fcontent%2fAsthma.jpg&h=410&w=728&q=75&v=cc2c1ec47c&c=1)
Short of breath? Chinese PE firms place bets on chronic respiratory disease
As global investment into healthcare dips, some pre-IPO investors hold high hopes one Chinese pharma company can take on AstraZeneca and win big in the China respiratory drug market.
January 05, 2020